drugset / Trial / NCT00430937

Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections

NCT00430937

Phase 3 Terminated 194 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupSingle-blindTreatment

Summary

This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections

Timeline

Start
2006-04
Primary completion
2008-03
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Daptomycin Other / unclassified 4 mg/kg Intravenous
Comparator Teicoplanin Other / unclassified 400 mg Intravenous
Comparator Vancomycin Other / unclassified 1 g Intravenous

Indications